Abstract
Purpose: (1) To improve survival rates in patients with Ewing's sarcoma (ES) or peripheral neuroectodermal tumours (PNET) using semi-continuous chemotherapy and aiming to peform surgery in all; (2) To identify early prognostic factors to tailor therapy for future studies. Patients and methods One hundred and forty-one patients were entered onto the trial between January 1988 and December 1991. Induction therapy consisted of five courses of Cytoxan, 150 mg/m2 × 7 days, followed by Doxorubicin, 35 mg/m2 i.v on day 8 given at short intervals. Surgery was recommended whenever possible. The delivery of radiation therapy was based on the quality of resection and the histological response to CT. Maintenance chemotherapy consisted of vincristine + actinomycin and cytoxan + doxorubicin. The total duration of therapy was 10 months. Results After a median follow-up of 8.5 years, the projected overall survival at 5 years was 66% and disease-free survival (DFS) was 58%. In patients treated by surgery, only the histological response to CT had an influence on survival: 75% DFS for patients with a good histological response (less than 5% of cells), 48% for intermediate responders and only 20% for poor responders (≥ 30% of cells), P < 0.0001. The initial tumor volume by itself had no influence on DFS in these patients. In contrast, the tumour volume had a strong impact on DFS in patients treated by radiation therapy alone. Age had no impact on outcome. Conclusion Therapeutic trials for localized Ewing's sarcoma should be based on the histological response to chemotherapy or on the tumour volume according to the modality used for local therapy. © 2001 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Arai Y (1991) Ewing's sarcoma: local tumor control and patterns of failure following limited-volume radiation therapy. Int J Radiat Oncol Bio Phys 21: 1501–1508
Bacci G (2000) Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli. J Clin Oncol 18: 4–11
Bacci G (1985) Localized Ewing's sarcoma of bone: ten years’ experience at the Istituto Ortopedico Rizzoli in 124 cases treated with multimodal therapy. Eur J Cancer Clin Oncol 21: 163–173
Bacci G (2000) Neoadjuvant chemotherapy for Ewing's sarcoma of bone in patients older than thirty-nine years [In Process Citation]. Acta Oncol 39: 111–116
Barbieri E (1990) Combined therapy of localized Ewing's sarcoma of bone: analysis of results in 100 patients. Int J Radiat Oncol Biol Phys 19: 1165–1170
Craft AW (1997) Long-term results from the first UKCCSG Ewing's Tumour Study (ET-1). United Kingdom Children's Cancer Study Group (UKCCSG) and the Medical Research Council Bone Sarcoma Working Party. Eur J Cancer 33: 1061–1069
Donaldson SS (1998) A multidisciplinary study investigating radiotherapy in Ewing's sarcoma: end results of POG #8346. Pediatric Oncology Group. Int J Radiat Oncol Biol Phys 42: 125–135
Glasser DB (1992) Survival, prognosis, and therapeutic response in osteogenic sarcoma. The Memorial Hospital experience. Cancer 69: 698–708
Gobel V (1987) Prognostic significance of tumor volume in localized Ewing's sarcoma of bone in children and adolescents. J Cancer Res Clin Oncol 113: 187–191
Hayes FA (1983) The response of Ewing's sarcoma to sequential cyclophosphamide and adriamycin induction therapy. J Clin Oncol 1: 45–51
Hayes FA (1989) Therapy for localized Ewing's sarcoma of bone. J Clin Oncol 7: 208–213
Hense HW (1999) Factors associated with tumor volume and primary metastases in Ewing tumors: results from the (EI)CESS studies. Ann Oncol 10: 1073–1077
Huvos AG, Rosen G and Marcove RC (1977) Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy en bloc resection, and prosthetic bone replacement. Arch Pathol Lab Med 101: 14–18
Jurgens H (1988a) [The German Society of Pediatric Oncology Cooperative Ewing Sarcoma Studies CESS 81/86: report after 6 1/2 years]. [German]. Klinische Padiatrie 200: 243–252
Jurgens H (1988b) Multidisciplinary treatment of primary Ewing's sarcoma of bone. A 6-year experience of a European Cooperative Trial. Cancer 61: 23–32
Jurgens H, Paulussen M and Roessner A (1993) Neural differenciation in small cell sarcomas of bone in children and adolescents: Implications for treatment?. Proc Am Soc Clin Oncol 12: 1415(Abstract)
Kaplan ES and Meier P (1958) Non-parametric estimation from incomplete observation. J Am Stat Assoc 53: 457–480
Kinsella TJ (1991) Long-term follow-up of Ewing's sarcoma of bone treated with combined modality therapy [see comments]. Int J Radiat Onc Biol Phy 20: 389–395
Mendenhall CM (1983) The prognostic significance of soft tissue extension in Ewing's sarcoma. Cancer 51: 913–917
Nesbit ME (1990) Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long-term follow-up of the First Intergroup study. J Clin Oncol 8: 1664–1674
Oberlin O (1985) The response to initial chemotherapy as a prognostic factor in localized Ewing's sarcoma. Eur J Cancer Clin Oncol 21: 463–467
Oberlin O (1992) No benefit of ifosfamide in Ewing's sarcoma: a nonrandomized study of the French Society of Pediatric Oncology. J Clin Oncol 10: 1407–1412
Parham DM (1999) Neuroectodermal differentiation in Ewing's sarcoma family of tumors does not predict tumor behavior. Hum Pathol 30: 911–918
Peto R (1977) Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer 35: 1–39
Picci P (1993) Prognostic significance of histopathologic response to chemotherapy in nonmetastatic Ewing's sarcoma of the extremities. J Clin Oncol 11: 1763–1769
Sauer R (1987) Prognostic factors in the treatment of Ewing's sarcoma. The Ewing's Sarcoma Study Group of the German Society of Paediatric Oncology CESS 81. Radiother Oncol 10: 101–110
Terrier P (1995) Is neuro-ectodermal differentiation of Ewing's sarcoma of bone associated with an unfavourable prognosis?. Eur J Cancer 31A: 307–314
Wilkins RM (1986) Ewing's sarcoma of bone. Experience with 140 patients. Cancer 58: 2551–2555
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Oberlin, O., Deley, M., Bui, B. et al. Prognostic factors in localized Ewing's tumours and peripheral neuroectodermal tumours: the third study of the French Society of Paediatric Oncology (EW88 study). Br J Cancer 85, 1646–1654 (2001). https://doi.org/10.1054/bjoc.2001.2150
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2001.2150
Keywords
This article is cited by
-
Survival and treatment in older patients with ewing sarcoma: an analysis of the national cancer database
European Journal of Medical Research (2024)
-
Improving quality and quantity of life for childhood cancer survivors globally in the twenty-first century
Nature Reviews Clinical Oncology (2023)
-
Easy-to-use clinical tool for survival estimation in Ewing sarcoma at diagnosis and after surgery
Scientific Reports (2019)
-
Sinusoidal obstruction syndrome/veno-occlusive disease after high-dose intravenous busulfan/melphalan conditioning therapy in high-risk Ewing Sarcoma
Bone Marrow Transplantation (2018)